Anti-IL5 therapies for asthma

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Interleukin-5 (IL-5) is a key cytokine in eosinophil activation, driving airway inflammation in asthma.
• Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) are emerging therapies for asthma management.
• These targeted therapies show promise in reducing exacerbations and improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of anti-IL-5 therapies versus placebo in adults and children with chronic asthma.
• To specifically assess outcomes in patients with eosinophilic asthma refractory to existing treatments.
• To compare effects on asthma exacerbations, health-related quality of life (HRQoL), and lung function.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Included studies compared mepolizumab, reslizumab, and benralizumab against placebo.
• Data extraction and analysis followed Cochrane methods, using a random-effects model.

Main Results:

• Anti-IL-5 treatments approximately halved exacerbation rates in severe eosinophilic asthma.
• Modest, though not always clinically significant, improvements in HRQoL scores were noted.
• Small, statistically significant improvements in lung function (FEV1) were observed across treatments.
• No excess serious adverse events were reported for mepolizumab or reslizumab; benralizumab showed a slight increase in discontinuations.

Conclusions:

• Anti-IL-5 therapies are effective adjuncts for severe eosinophilic asthma, significantly reducing exacerbations.
• Evidence for clinically meaningful improvements in HRQoL and lung function is limited.
• Further research is required for non-eosinophilic asthma, pediatric populations, and long-term treatment effects.